PMID- 35421452
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220517
IS  - 1879-0631 (Electronic)
IS  - 0024-3205 (Linking)
VI  - 300
DP  - 2022 Jul 1
TI  - Characteristics and molecular mechanisms through which SGLT2 inhibitors improve 
      metabolic diseases: A mechanism review.
PG  - 120543
LID - S0024-3205(22)00243-0 [pii]
LID - 10.1016/j.lfs.2022.120543 [doi]
AB  - Metabolic diseases, such as diabetes, gout and hyperlipidemia are global health 
      challenges. Among them, diabetes has been extensively investigated. Type 2 
      diabetes mellitus (T2DM), which is characterized by hyperglycemia, is a complex 
      metabolic disease that is associated with various metabolic disorders. The newly 
      developed oral hypoglycemic agent, sodium-glucose cotransporter 2 (SGLT2) 
      inhibitor, has been associated with glucose-lowering effects and it affects 
      metabolism in various ways. However, the potential mechanisms of SGLT2 inhibitors 
      in metabolic diseases have not fully reviewed. Many of the effects beyond 
      glycemic control must be considered off-target effects. Therefore, we reviewed 
      the effects of SGLT2 inhibitors on metabolic diseases such as obesity, 
      hypertension, hyperlipidemia, hyperuricemia, fatty liver disease, insulin 
      resistance, osteoporosis and fractures. Moreover, we elucidated their molecular 
      mechanisms to provide a theoretical basis for metabolic disease treatment.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Lingli, Xie
AU  - Lingli X
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China; Hubei Provincial Clinical 
      Research Center for Diabetes and Metabolic Disorders, Wuhan, China.
FAU - Wenfang, Xia
AU  - Wenfang X
AD  - Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, China; Hubei Provincial Clinical 
      Research Center for Diabetes and Metabolic Disorders, Wuhan, China. Electronic 
      address: xiawenfang@hust.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220412
PL  - Netherlands
TA  - Life Sci
JT  - Life sciences
JID - 0375521
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/metabolism
MH  - Glucose
MH  - Humans
MH  - *Hyperlipidemias/complications
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/pharmacology/therapeutic use
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Metabolic diseases
OT  - Molecular mechanism
OT  - Off-target effects
OT  - SGLT2 inhibitors
EDAT- 2022/04/15 06:00
MHDA- 2022/05/18 06:00
CRDT- 2022/04/14 20:10
PHST- 2021/11/30 00:00 [received]
PHST- 2022/04/07 00:00 [revised]
PHST- 2022/04/08 00:00 [accepted]
PHST- 2022/04/15 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2022/04/14 20:10 [entrez]
AID - S0024-3205(22)00243-0 [pii]
AID - 10.1016/j.lfs.2022.120543 [doi]
PST - ppublish
SO  - Life Sci. 2022 Jul 1;300:120543. doi: 10.1016/j.lfs.2022.120543. Epub 2022 Apr 
      12.